HomeMarket NewsMediWound burn therapy NexoBrid launched in US

MediWound burn therapy NexoBrid launched in US

Actionable Trade Ideas

always free

Dressing burned wound


Israeli biopharmaceutical company MediWound (NASDAQ:MDWD) announced the commercial launch of NexoBrid, its advanced wound care solution, in the United States. This launch was made possible through a partnership with Vericel.

NexoBrid, also referred to as anacaulase-bcdb, is a groundbreaking enzymatic therapy that effectively removes non-viable tissue from severe burn patients, without the need for surgery. Moreover, it helps protect viable tissue, which can be at risk during surgical removal. As a result, the use of NexoBrid potentially minimizes the need for subsequent skin grafting.

The product has received approvals in more than 40 countries, including the United States, European Union, and Japan. In Japan, it has been granted orphan drug status by the regulatory authorities.

Swing Trading Ideas and Market Commentary

Need some new swing ideas? Get free weekly swing ideas and market commentary from Jonathan Bernstein here: Swing Trading.

Explore More

Weekly In-Depth Market Analysis and Actionable Trade Ideas

Get institutional-level analysis and trade ideas to take your trading to the next level, sign up for free and become apart of the community.